Features

Early Post-RP Complications Tied to Age

The risk of virtually all early postoperative complications increases with increasing patient age at radical prostatectomy for localized prostate cancer.

PCa Phenotype May Predict Response to Immune Checkpoint Blockade

The MSI-H/dMMR phenotype in men with advanced PCa is associated with greater likelihood of a durable response to PD-1/PD-L1 inhibitors.

Prostate Cancer Detection Improved With Combined Biopsy Targeting

In a study, visual registration in conjunction with image fusion resulted in the highest detection rate of clinically significant prostate cancer.

Ultrasound + MRI Improves High-Grade Prostate Cancer Detection

Well demarcated hypoechoic areas in suspicious regions on MRI identify men more likely to have Gleason 7 or higher prostate cancer found on biopsy.

Delayed PCa Tx May Up Relapse

Patients whose radical prostatectomy was delayed more than 6 months had a nearly 2-fold increased risk of biochemical recurrence, a study found.

Latest Prostate Cancer News

Prostate Cancer Risk After Single Negative Biopsy Quantified

Prostate Cancer Risk After Single Negative Biopsy Quantified

Men with a single negative prostate biopsy have a 20-year cumulative rate of prostate cancer diagnosis of 23.7%.

Online Calculator May Aid In Individualizing Prostate Cancer Care

Online Calculator May Aid In Individualizing Prostate Cancer Care

New tool promises to help patients decide whether radical prostatectomy or radiation therapy is their best treatment option.

Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients

Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients

This survey assessed the opinions of oncologists, urologists, and oncology nurses on the use of shared decision-making in older men with metastatic castration-resistant prostate cancer.

Obesity Linked With Improved Survival in mCRPC

Obesity Linked With Improved Survival in mCRPC

Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.

Radium-223 Use in mCRPC Differs By Race

Radium-223 Use in mCRPC Differs By Race

Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.

Newer mCRPC Drugs Led to Longer Survival in African American Patients

Newer mCRPC Drugs Led to Longer Survival in African American Patients

The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.

Darolutamide Improves Metastasis-Free Survival in CRPC

Darolutamide Improves Metastasis-Free Survival in CRPC

Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months.

PCa Grade Group Better Predicts Pathologic Outcomes, Recurrence

PCa Grade Group Better Predicts Pathologic Outcomes, Recurrence

In a "real world" study, biopsy and surgical grade groups 2, 3, 4, and 5 each were associated with incrementally higher risks for adverse pathologic features and biochemical recurrence.

Guidelines for Germline Genetic Testing in PCa Insufficient

Guidelines for Germline Genetic Testing in PCa Insufficient

A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.

Prostate Cancer Active Surveillance Increasing in the US

Prostate Cancer Active Surveillance Increasing in the US

From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.

Low Carb Diet + Walking May Ease ADT's Adverse Effects

Low Carb Diet + Walking May Ease ADT's Adverse Effects

In a small study, men on androgen deprivation therapy for prostate cancer lost weight and experienced improved hemoglobin A1C and lipid profiles.

Sign up for free e-Newsletters